002317 众生药业
已收盘 04-30 15:00:00
资讯
新帖
简况
去年亏损近3亿元，子公司IPO失利，众生药业能否迎来转机？
新京报 · 04-29
去年亏损近3亿元，子公司IPO失利，众生药业能否迎来转机？
图解众生药业年报：第四季度单季净利润同比减2661.34%
证券之星 · 04-26
图解众生药业年报：第四季度单季净利润同比减2661.34%
图解众生药业一季报：第一季度单季净利润同比增61.06%
证券之星 · 04-25
图解众生药业一季报：第一季度单季净利润同比增61.06%
众生药业：公司会充分结合实际，积极使用新技术，探索新技术的无限可能
证券之星 · 04-23
众生药业：公司会充分结合实际，积极使用新技术，探索新技术的无限可能
A股午后医药板块持续走高，创新药方向继续领涨，众生药业、华森制药、富士莱涨停，百利天恒、诺诚健华、新诺威、百济神州创历史
美港电讯 · 04-22
A股午后医药板块持续走高，创新药方向继续领涨，众生药业、华森制药、富士莱涨停，百利天恒、诺诚健华、新诺威、百济神州创历史
A股中药板块异动拉升，华森制药、众生药业午后双双涨停，康缘药业、以岭药业、同仁堂、大唐药业等涨幅居前。
美港电讯 · 04-22
A股中药板块异动拉升，华森制药、众生药业午后双双涨停，康缘药业、以岭药业、同仁堂、大唐药业等涨幅居前。
【中药概念股表现活跃 众生药业涨超6%】 中药概念股表现活跃，众生药业涨超6%，同仁堂、云南白药、方盛制药、马应龙等股上涨。
金融界 · 04-22
【中药概念股表现活跃 众生药业涨超6%】 中药概念股表现活跃，众生药业涨超6%，同仁堂、云南白药、方盛制药、马应龙等股上涨。
A股中药概念股表现活跃，众生药业涨超6%，同仁堂、云南白药、方盛制药、马应龙等股上涨。
美港电讯 · 04-22
A股中药概念股表现活跃，众生药业涨超6%，同仁堂、云南白药、方盛制药、马应龙等股上涨。
众生药业：公司将继续紧跟国家政策导向推动新药研发进程
证券之星 · 03-10
众生药业：公司将继续紧跟国家政策导向推动新药研发进程
众生药业：创新药研发是医药企业实现长期发展的必由之路
证券之星 · 03-10
众生药业：创新药研发是医药企业实现长期发展的必由之路
众生药业：公司始终依法合规使用募集资金
证券之星 · 03-10
众生药业：公司始终依法合规使用募集资金
众生药业：公司赎回控股子公司部分股权事项不存在损害股东利益情形
证券之星 · 03-10
众生药业：公司赎回控股子公司部分股权事项不存在损害股东利益情形
众生药业：RAY1225注射液III期临床试验获得组长单位伦理批件
证券之星 · 03-10
众生药业：RAY1225注射液III期临床试验获得组长单位伦理批件
众生药业：昂拉地韦片已完成与奥司他韦胶囊头对头III期临床试验并获积极结果
证券之星 · 03-10
众生药业：昂拉地韦片已完成与奥司他韦胶囊头对头III期临床试验并获积极结果
众生药业：RAY1225注射液治疗超重/肥胖III期临床试验获批，产品研发进入关键阶段
证券之星 · 03-10
众生药业：RAY1225注射液治疗超重/肥胖III期临床试验获批，产品研发进入关键阶段
众生药业：公司赎回控股子公司部分股权事项已按规定审议批准
证券之星 · 03-10
众生药业：公司赎回控股子公司部分股权事项已按规定审议批准
众生药业：公司不存在应披露而未披露事项，专注主营提升内在价值
证券之星 · 03-06
众生药业：公司不存在应披露而未披露事项，专注主营提升内在价值
众生药业：睿创融资方案符合法律法规，不存在损害公司及股东利益情形
证券之星 · 03-06
众生药业：睿创融资方案符合法律法规，不存在损害公司及股东利益情形
众生药业：公司不存在您所述的情况
证券之星 · 03-04
众生药业：公司不存在您所述的情况
加载更多
公司概况
公司名称：
广东众生药业股份有限公司
所属行业：
医药制造业
上市日期：
2009-12-11
主营业务：
广东众生药业股份有限公司主营业务是药品研发、生产、销售。公司主要产品有复方血栓通系列产品、众生丸系列产品、头孢克肟分散片、头孢拉定胶囊、硫糖铝口服混悬液。公司为高新技术企业。公司入选“2022中国医药创新企业100强”、“2021年度中国医药工业百强”、“2022年广东省制造业企业500强”。
发行价格：
55.00
{"stockData":{"symbol":"002317","market":"SZ","secType":"STK","nameCN":"众生药业","latestPrice":11.13,"timestamp":1745996616000,"preClose":11.24,"halted":0,"volume":17433100,"delay":0,"changeRate":-0.0098,"floatShares":762000000,"shares":852000000,"eps":-0.3146,"marketStatus":"已收盘","change":-0.11,"latestTime":"04-30 15:00:00","open":11.28,"high":11.35,"low":11.12,"amount":195000000,"amplitude":0.0205,"askPrice":11.14,"askSize":91,"bidPrice":11.13,"bidSize":348,"shortable":0,"etf":0,"ttmEps":-0.3146,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1746495000000},"marketStatusCode":5,"adr":0,"adjPreClose":11.24,"symbolType":"stock","openAndCloseTimeList":[[1745976600000,1745983800000],[1745989200000,1745996400000]],"highLimit":12.36,"lowLimit":10.12,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":851556477,"isCdr":false,"pbRate":2.4,"roa":"--","roe":"2.09%","epsLYR":-0.36,"committee":0.542926,"marketValue":9478000000,"turnoverRate":0.0229,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2025-05-06。","floatMarketCap":8477000000},"requestUrl":"/m/hq/s/002317","defaultTab":"news","newsList":[{"id":"2531213473","title":"去年亏损近3亿元，子公司IPO失利，众生药业能否迎来转机？","url":"https://stock-news.laohu8.com/highlight/detail?id=2531213473","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531213473?lang=zh_cn&edition=full","pubTime":"2025-04-29 09:16","pubTimestamp":1745889360,"startTime":"0","endTime":"0","summary":"2025年一季度，众生药业业绩回暖，营收虽有所下滑，但净利润实现同比增长。计提资产减值损失减少净利润4.84亿元众生药业去年亏损近3亿元，主要系计提大额资产减值损失减少报告期归属于上市公司股东的净利润4.84亿元。2019年、2020年分别对两家公司计提商誉减值，也是因此，2020年众生药业出现上市后首亏。创新药子公司IPO未果被“退股”为了推进创新药物的研发，2018年，众生药业设立子公司众生睿创，重点布局呼吸系统和代谢性疾病领域创新药物。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2025-04-29/doc-ineuuwac5882809.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-04-29/doc-ineuuwac5882809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0188","BK0239","BK0077","002317"],"gpt_icon":0},{"id":"2530919190","title":"图解众生药业年报：第四季度单季净利润同比减2661.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530919190","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530919190?lang=zh_cn&edition=full","pubTime":"2025-04-26 08:34","pubTimestamp":1745627651,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业2024年年报显示，公司主营收入24.67亿元，同比下降5.48%；归母净利润-2.99亿元，同比下降213.63%；扣非净利润-2.6亿元，同比下降185.41%；其中2024年第四季度，公司单季度主营收入5.59亿元，同比上升3.73%；单季度归母净利润-4.48亿元，同比下降2661.34%；单季度扣非净利润-4.49亿元，同比下降9628.75%；负债率27.79%，投资收益2486.9万元，财务费用882.71万元，毛利率56.03%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042600008718.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317"],"gpt_icon":0},{"id":"2530161938","title":"图解众生药业一季报：第一季度单季净利润同比增61.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530161938","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530161938?lang=zh_cn&edition=full","pubTime":"2025-04-26 03:02","pubTimestamp":1745607773,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业2025年一季报显示，公司主营收入6.34亿元，同比下降1.07%；归母净利润8261.18万元，同比上升61.06%；扣非净利润7843.48万元，同比上升8.6%；负债率21.76%，投资收益417.96万元，财务费用-2.35万元，毛利率56.58%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042600001171.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317"],"gpt_icon":0},{"id":"2529843511","title":"众生药业：公司会充分结合实际，积极使用新技术，探索新技术的无限可能","url":"https://stock-news.laohu8.com/highlight/detail?id=2529843511","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529843511?lang=zh_cn&edition=full","pubTime":"2025-04-23 11:36","pubTimestamp":1745379376,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业(002317)04月22日在投资者关系平台上答复投资者关心的问题。投资者提问：猎聘网上显示贵司正在招聘 AIDD/CADD研发人员，负责 AI 药物设计、AI模型研发，在推进 AI药物研发方面有什么具体规划和举措？众生药业回复：您好！此为公司创新药研发平台众生睿创的招聘信息，公司坚持研发创新是第一生产力的发展理念，把发展新质生产力作为自身发展的重要路径，公司会充分结合实际，积极使用新技术，探索新技术的无限可能。谢谢！以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042300017059.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","BK0188","002317"],"gpt_icon":0},{"id":"2529701316","title":"A股午后医药板块持续走高，创新药方向继续领涨，众生药业、华森制药、富士莱涨停，百利天恒、诺诚健华、新诺威、百济神州创历史","url":"https://stock-news.laohu8.com/highlight/detail?id=2529701316","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529701316?lang=zh_cn&edition=full","pubTime":"2025-04-22 13:47","pubTimestamp":1745300842,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["688506","159992","688235","BK0196","BK1588","LU0307460666.USD","BK1583","BK1191","002317","01349","002907","300765","BK0077","688091","09969","BK4139","688428","BK1574","301258","399300","159982","ONC","688068","688505","BK0188","159938","BK1500","06978","002294","06160","BK0226","BK0183","LU0588546209.SGD","LU1969619763.USD","LU2328871848.SGD","BK0028","BK1161","09939","BK1515","BK0239","BK0187"],"gpt_icon":0},{"id":"2529316873","title":"A股中药板块异动拉升，华森制药、众生药业午后双双涨停，康缘药业、以岭药业、同仁堂、大唐药业等涨幅居前。","url":"https://stock-news.laohu8.com/highlight/detail?id=2529316873","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529316873?lang=zh_cn&edition=full","pubTime":"2025-04-22 13:39","pubTimestamp":1745300355,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["002317","BK0239","BK0046","399300","BK0042","600085","BK0097","BK0188","BK0077","BK0113","BK0012","BK0086","BK0183","LU1688375341.USD","BK0196","BK0028","600557","002907","002603","159982"],"gpt_icon":0},{"id":"2529036793","title":"【中药概念股表现活跃 众生药业涨超6%】 中药概念股表现活跃，众生药业涨超6%，同仁堂、云南白药、方盛制药、马应龙等股上涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2529036793","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529036793?lang=zh_cn&edition=full","pubTime":"2025-04-22 09:56","pubTimestamp":1745287019,"startTime":"0","endTime":"0","summary":"中药概念股表现活跃，众生药业涨超6%，同仁堂、云南白药、方盛制药、马应龙等股上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/22095649737792.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0164","603998","600993","BK0097","BK0196","BK0086","BK0239","BK0060","BK0096","BK0012","BK0077","000538","BK0175","LU1688375341.USD","002317","BK0187","BK0188","600085","BK0183","BK0113","BK0028"],"gpt_icon":0},{"id":"2529367510","title":"A股中药概念股表现活跃，众生药业涨超6%，同仁堂、云南白药、方盛制药、马应龙等股上涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2529367510","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529367510?lang=zh_cn&edition=full","pubTime":"2025-04-22 09:56","pubTimestamp":1745286967,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0012","BK0113","BK0187","LU1688375341.USD","000538","BK0196","399300","600085","BK0086","BK0164","BK0183","002317","BK0028","BK0096","BK0097","BK0077","BK0175","603998","600993","BK0188","159982","BK0060","BK0239"],"gpt_icon":0},{"id":"2518367295","title":"众生药业：公司将继续紧跟国家政策导向推动新药研发进程","url":"https://stock-news.laohu8.com/highlight/detail?id=2518367295","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518367295?lang=zh_cn&edition=full","pubTime":"2025-03-10 15:06","pubTimestamp":1741590380,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业(002317)03月10日在投资者关系平台上答复投资者关心的问题。投资者提问：国家近期出台了一系列支持创新药发展的政策，公司如何抓住这一机遇？众生药业回复：您好！国家政策对创新药的支持为行业发展注入了强劲动力。公司将继续紧跟国家政策导向，对于有助于公司的相关政策，公司积极沟通并争取获得相关政策支持，推动新药研发进程。同时，公司专注主业，积极做好经营管理等工作，不断提升公司内在价值，通过健康的发展切实维护广大投资者利益，为股东带来更好的回报。谢谢！以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031000013856.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","002317","BK0188"],"gpt_icon":0},{"id":"2518268627","title":"众生药业：创新药研发是医药企业实现长期发展的必由之路","url":"https://stock-news.laohu8.com/highlight/detail?id=2518268627","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518268627?lang=zh_cn&edition=full","pubTime":"2025-03-10 11:37","pubTimestamp":1741577837,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业03月10日在投资者关系平台上答复投资者关心的问题。创新药研发确实具有高投入、高风险的特点，但这也是医药企业实现长期发展的必由之路。公司按照“中药为基、创新引领，聚焦特色的医药健康企业”的战略目标定位，始终坚持以创新驱动发展，聚焦代谢性疾病、呼吸系统疾病等领域，积极推进创新药研发。未来伴随着更多产品的上市，也将为公司的盈利能力提供助力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031000010448.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0077","159992","002317","BK0239","BK1574","BK0188","06978"],"gpt_icon":0},{"id":"2518426862","title":"众生药业：公司始终依法合规使用募集资金","url":"https://stock-news.laohu8.com/highlight/detail?id=2518426862","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518426862?lang=zh_cn&edition=full","pubTime":"2025-03-10 11:37","pubTimestamp":1741577836,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业(002317)03月10日在投资者关系平台上答复投资者关心的问题。投资者提问：公司有考虑将募集资金用于其他热门赛道以扩大公司盈利能力吗？众生药业回复：您好！公司始终依法合规使用募集资金，公司严格按照规则要求履行信息披露义务，关于募集资金的使用和规划情况请您以公司公告信息为准。谢谢！以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031000010447.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0077","BK0188","BK0239"],"gpt_icon":0},{"id":"2518268625","title":"众生药业：公司赎回控股子公司部分股权事项不存在损害股东利益情形","url":"https://stock-news.laohu8.com/highlight/detail?id=2518268625","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518268625?lang=zh_cn&edition=full","pubTime":"2025-03-10 11:37","pubTimestamp":1741577828,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业(002317)03月10日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司是不是推动子公司上市的过程中有损害了母公司的股东的利益行为？众生药业回复：您好！公司赎回控股子公司部分股权事项，已经公司董事会、股东大会审议批准，本次交易遵循公平、公正、公开的原则，符合有关法律、法规的规定，不存在损害公司及公司股东利益的情形。具体情况详见公司刊载在《证券时报》和巨潮资讯网（www.cninfo.com.cn）的相关公告。谢谢！以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031000010438.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0077","002317"],"gpt_icon":0},{"id":"2518268658","title":"众生药业：RAY1225注射液III期临床试验获得组长单位伦理批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2518268658","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518268658?lang=zh_cn&edition=full","pubTime":"2025-03-10 11:37","pubTimestamp":1741577823,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业(002317)03月10日在投资者关系平台上答复投资者关心的问题。投资者提问：RAY1225注射液的III期临床试验预计何时完成？众生药业回复：您好！RAY1225注射液的临床试验目前进展顺利，并于近日获得RAY1225注射液治疗超重/肥胖参与者的III期临床试验组长单位伦理批件，众生睿创将在全国主要研究者的带领下，按照相关要求高质量、加速度、科学规范地推进III期临床试验。公司将及时依据信息披露规则履行信息披露责任。谢谢！以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031000010431.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002317","BK1141","BK0239","BK0077","BK1583","03347","BK1576"],"gpt_icon":0},{"id":"2518621268","title":"众生药业：昂拉地韦片已完成与奥司他韦胶囊头对头III期临床试验并获积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2518621268","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518621268?lang=zh_cn&edition=full","pubTime":"2025-03-10 11:36","pubTimestamp":1741577817,"startTime":"0","endTime":"0","summary":"昂拉地韦片作为国内第一个获批临床的甲型流感病毒RNA聚合酶抑制剂，临床前研究结果表明，对包括奥司他韦耐药株、高致病性禽流感病毒株和巴洛沙韦耐药株等在内的多种不同亚型流感病毒株具有强大的抑制活性，已完成与奥司他韦胶囊头对头、安慰剂对照治疗成人甲型流感的III期临床试验结果表明：该试验获得了积极结果，本研究已达到方案预设的主要疗效终点指标，且安全性良好。目前昂拉地韦片正在审评审批阶段，并按照CDE要求正常推进中。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031000010424.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK1576","03347","002317","BK1141","BK1583","BK0077"],"gpt_icon":0},{"id":"2518268646","title":"众生药业：RAY1225注射液治疗超重/肥胖III期临床试验获批，产品研发进入关键阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2518268646","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518268646?lang=zh_cn&edition=full","pubTime":"2025-03-10 11:36","pubTimestamp":1741577817,"startTime":"0","endTime":"0","summary":"投资者提问：一直很关注公司减肥药的进展，看到RAY1225注射液的III期临床试验获批了，这对公司未来业绩有何影响？RAY1225注射液治疗超重/肥胖参与者的III期临床试验组长单位伦理批件的获得，标志着该产品研发进入关键阶段，未来若顺利上市，对公司业绩具有积极作用。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031000010426.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK1576","BK1141","BK0077","03347","BK0188","BK1583","BK0239"],"gpt_icon":0},{"id":"2518268623","title":"众生药业：公司赎回控股子公司部分股权事项已按规定审议批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2518268623","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518268623?lang=zh_cn&edition=full","pubTime":"2025-03-10 11:36","pubTimestamp":1741577811,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业03月10日在投资者关系平台上答复投资者关心的问题。反正当初实施时没有公布赎回条件，如今可以信口雌黄，为投机资本保本保高额利息服务，诠释贵公司的服务宗旨。公司赎回控股子公司部分股权事项，已经公司董事会、股东大会审议批准，本次交易遵循公平、公正、公开的原则，符合有关法律、法规的规定，不存在损害公司及公司股东利益的情形。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031000010420.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","002317","BK0188","BK0239"],"gpt_icon":0},{"id":"2517180988","title":"众生药业：公司不存在应披露而未披露事项，专注主营提升内在价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2517180988","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517180988?lang=zh_cn&edition=full","pubTime":"2025-03-06 16:06","pubTimestamp":1741248372,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业03月06日在投资者关系平台上答复投资者关心的问题。公司始终坚持合规经营，规范披露，严格依据信息披露规则履行信息披露责任，不存在应披露而未披露事项。公司按照“中药为基、创新引领，聚焦特色的医药健康企业”的战略目标定位，专注主业，积极做好经营管理、产品研发等工作，不断提升公司内在价值，通过健康的发展切实维护广大投资者利益，为股东带来更好的回报。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030600025483.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","002317","BK0077"],"gpt_icon":0},{"id":"2517180902","title":"众生药业：睿创融资方案符合法律法规，不存在损害公司及股东利益情形","url":"https://stock-news.laohu8.com/highlight/detail?id=2517180902","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517180902?lang=zh_cn&edition=full","pubTime":"2025-03-06 16:03","pubTimestamp":1741248190,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业(002317)03月06日在投资者关系平台上答复投资者关心的问题。投资者提问：贵司在众生睿创融资结构设计上，是不是有转移风险至上市公司操作，尤其是B、C轮融资中，机构投资者通过“本金+利息”或“本金回购”条款降低风险？众生药业回复：您好，睿创融资方案是双方经慎重考虑和谈判后达成的，也符合相关法律法规的要求，不存在损害公司及公司股东利益的情形。谢谢！以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030600025117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0239","BK0188","BK0077"],"gpt_icon":0},{"id":"2516361527","title":"众生药业：公司不存在您所述的情况","url":"https://stock-news.laohu8.com/highlight/detail?id=2516361527","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516361527?lang=zh_cn&edition=full","pubTime":"2025-03-04 12:00","pubTimestamp":1741060842,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业(002317)03月03日在投资者关系平台上答复投资者关心的问题。投资者：贵公司突然宣布B轮融资赎回条件，为投机资本保本保高额利息牟利，上市公司亏损。然后睿创低价打包出售，投机资本获得带血廉价筹码。贵公司会这样操作吗？众生药业董秘：您好，公司不存在您所述的情况。谢谢！以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030400017797.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","002317","BK0077"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1746167994526,"stockEarnings":[{"period":"1week","weight":-0.0313},{"period":"1month","weight":0.0164},{"period":"3month","weight":0.048},{"period":"6month","weight":-0.1318},{"period":"1year","weight":-0.256},{"period":"ytd","weight":-0.084}],"compareEarnings":[{"period":"1week","weight":-0.0053},{"period":"1month","weight":-0.017},{"period":"3month","weight":0.0087},{"period":"6month","weight":0.0021},{"period":"1year","weight":0.0561},{"period":"ytd","weight":-0.0217}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"广东众生药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"91109人(较上一季度增加2.82%)","perCapita":"8359股","listingDate":"2009-12-11","address":"广东省东莞市石龙镇西湖工业区信息产业园","registeredCapital":"85155万元","survey":" 广东众生药业股份有限公司主营业务是药品研发、生产、销售。公司主要产品有复方血栓通系列产品、众生丸系列产品、头孢克肟分散片、头孢拉定胶囊、硫糖铝口服混悬液。公司为高新技术企业。公司入选“2022中国医药创新企业100强”、“2021年度中国医药工业百强”、“2022年广东省制造业企业500强”。","listedPrice":55},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"众生药业(002317)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供众生药业(002317)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"众生药业,002317,众生药业股票,众生药业股票老虎,众生药业股票老虎国际,众生药业行情,众生药业股票行情,众生药业股价,众生药业股市,众生药业股票价格,众生药业股票交易,众生药业股票购买,众生药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"众生药业(002317)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供众生药业(002317)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}